Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives
CONCLUSIONS: Cellular therapy with MSCs is very promising and should be part of the treatment of AKI patients in combination with other approaches already available, helping to accelerate recovery and/or slow the progression to chronic kidney disease. Randomized, multicentre controlled studies are needed to develop robust protocols that validate population-based cell therapy with MSCs.
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
More News: Chemotherapy | Chronic Kidney Disease | General Medicine | Kidney Transplant | Kidney Transplantation | Stem Cell Therapy | Stem Cells | Study | Transplants | Urology & Nephrology